MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big pharma ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

What if you could see every angle of the market in one view? With Barchart’s Grid Charts, you can. Whether you’re scanning dozens of tickers, comparing multiple timeframes, or building a custom ...